The Global Market for Cancer Immunotherapy - Forecast to 2024: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 8, 2018--The “Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy), Application (Lung, Breast, Multiple Myeloma, Colorectal, Melanoma, Prostate), And End User- Global Forecast To 2024” report has been added to ResearchAndMarkets.com’s offering.
The global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to reach USD 152.83 billion by 2024.
The high growth of cancer immunotherapy market is attributed to factors such as rising incidence of cancer globally, rising adoption of cancer immunotherapies over other conventional cancer treatments owing to the increased survival rate and less side effects with immunotherapy drugs, increasing number of ongoing clinical trials with the help of rising investments by major players in the market, and development of bioinformatics tools that are enhancing the drug development process for cancer immunotherapy market.
However, the high cost of the cancer immunotherapy treatment is restricting the growth of this market to some extent. Apart from this, growing R&D investments by major players in the market to develop cancer immunotherapies and high growth prospects in the developing countries such as China and India provides significant opportunity in this market.
Monoclonal antibodies dominated the global cancer immunotherapy market, mainly due to their high adoption for cancer treatment, rising number of US FDA approvals, and better five-year survival rates as compared to other cancer treatment options available in the market.
Cancer immunotherapy market for lung cancer application commanded the largest share, mainly attributed to increasing incidence of lung cancer, the significant benefit of cancer immunotherapy for lung cancer compared with other treatment options, and rising adoption of immunotherapies in lung cancer owing to the higher survival rate.
DriversRising Cancer Incidence Growing Adoption of Immunotherapy over other Treatment Options Increasing Number of Technological Collaborations and Mergers Development of Bioinformatics Tools Enhancing Drug Development Process
RestraintsHigh Cost of Treatment
OpportunitiesGrowing R&D Expenditure High Growth Prospects in Emerging Economies
ChallengesLimited Funds with Small and Mid-Sized Organizations to Initiate the Clinical Trials Complexities of Tumor
Key Topics Covered1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Industry Insights
6. Cancer Immunotherapy Market, by Type
7. Cancer Immunotherapy Market, by Application
8. Cancer Immunotherapy Market, by End-User
9. Cancer Immunotherapy Market, by Region
10. Competitive Landscape
11. Company ProfilesAmgen Inc.BayerBristol-Myers SquibbCelgene CorporationDendreon PharmaceuticalsEli Lilly and CompanyF. Hoffmann-La RocheGilead Sciences Inc.Janssen Global Services LLCMerck & Co. Inc.NovartisPfizer Inc.
For more information about this report visit https://www.researchandmarkets.com/research/ssxbrz/the_global_market?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181108005637/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Genomics,Immune Disorders Drugs,Biopharmaceuticals ,Hematology ,Cancer Vaccines,Immunosuppressive Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/08/2018 10:57 AM/DISC: 11/08/2018 10:57 AM